Introduction
Skin carcinogenesis in the mouse model is a threestep process consisting of tumor initiation, tumor promotion and tumor progression (DiGiovanni, 1991 (DiGiovanni, , 1992 . While genetic events contribute essentially to initiation and progression, tumor promotion, which is a rate limiting step, in this model predominantly is characterized by epigenetic events. Two hallmarks of an eective tumor promotion have been identi®ed: chronic hyperproliferation and in¯ammation and thus, substances evoking such responses are potent tumor promoters (e.g. TPA). This paradigm also holds true for endogenous factors including but not limited to enzymes, transcription factors, cytokines and cytokine receptors. In general, overexpression of factors which evoke hyperproliferation and/or in¯am-mation render mice susceptible to skin carcinogenesis (Amendt et al., 1998; Cui et al., 1996; Megosh et al., 1995) . In addition to hyperproliferation and in¯ammation, modulation of apoptosis as a means to eliminate genetically damaged and transformed cells has been demonstrated to in¯uence skin tumor incidence (RodriguezVillanueva et al., 1998) .
Members of the transforming growth factor-û (TGF-û) superfamily of cytokines, including TGF-û1 ± 3, bone morphogenetic protein (BMP) -2, -4, -6 as well as activin have been shown to regulate epidermal cell proliferation (Blessing et al., 1996; Glick et al., 1993; Munz et al., 1999) , apoptosis (Guo and Kyprianou, 1999; Motyl et al., 1998; Teramoto et al., 1998) and in¯ammation (Blessing et al., 1996; Shull et al., 1992) . By modulating these crucial parameters, members of the TGF-b superfamily could play essential roles during the development of malignancies. For example, it has been shown that TGF-û1 acts as a tumor suppressor, most likely due to its growth inhibitory activity (Amendt et al., 1998; Cui et al., 1996; Massague et al., 2000) . Consistent with this view, both TGF-b1 as well as its speci®c type II receptor are upregulated during skin tumor promotion (Amendt et al., 1998; Pelton et al., 1991) .
Synthesis of BMP-6 in the epidermis of mice is seen ®rst at day 15.5 p.c., the onset of epidermal strati®cation, and persists till day 6 p.p. BMP-6 expression is limited to the dierentiated, postmitotic keratinocytes in the suprabasal layers of the interfollicular epidermis (Lyons et al., 1989; Wall et al., 1993) . Thereafter, in normal murine skin, expression of this factor declines to a very low level (Blessing et al., 1996; Wall et al., 1993) . However, expression of BMP-6 can be induced strongly under pathological conditions such as wounding (Kaiser et al., 1998) . In humans, BMP-6 expression has also been reported in some epithelial tumors including squamous cell carcinoma (Raida et al., 1999) , breast cancer cell lines and neoplastic salivary glands (Heikinheimo et al., 1999) . Additionally, BMP-6 was detected in skeletal metastases of prostate cancer (Autzen et al., 1998; Hamdy et al., 1997) .
The modulation of skin tumor promotion by TGF-b related growth factors occurs via the regulation of expression of the respective target genes. Known target genes for TGF-b and its relatives are the constituents of the transcription factor activator protein-1 (AP-1) (Choi et al., 1999; Hollnagel et al., 1999; Jonk et al., 1998; Ueyama et al., 1998) . AP-1 is composed of members of the Jun-(c-Jun, Jun B, Jun D) and Fos-families (c-Fos, Fos B, Fra 1, Fra 2) and acts as homo-or heterodimer (Angel and Karin, 1991) . In vivo experiments showed the requirement of c-Jun for the development of papillomas (Young et al., 1999) , whereas c-Fos is not essential for papilloma formation but is required for malignant transformation (Saez et al., 1995) .
Transgenic mouse strains which epidermally express BMP-6 under the control of the keratin 10 promoter show keratinocyte hyperproliferation as well as in¯am-mation (Blessing et al., 1996) . In this study we show that despite these two hallmarks of an eective tumor promotion BMP-6 overexpressing mice are resistant to chemically induced skin carcinogenesis most likely due to increased apoptotic frequencies and a downregulation of AP-1 constituents.
Results
Tumor promotion induces BMP-6 at the protein level but not on the mRNA level Expression of BMP-6 on the protein level was demonstrated by immunohistochemistry using a monoclonal and a polyclonal antibody speci®c for BMP-6. Both antibodies yielded comparable staining patterns. Perinatal skin of mice shows a strong BMP-6 speci®c reactivity which is limited to the outer suprabasal layers (Figure 1a ). In skin of adult mice, protein expression is downregulated to a very low level ( Figure  1b) . Strong induction of BMP-6 was detectable in the outer suprabasal layers of the skin 24 h after a single TPA treatment (Figure 1c) . Induced BMP-6 synthesis persisted at high levels and declined 96 h after treatment (data not shown). An even stronger induction of BMP-6 reactivity was seen after 8 weeks of repeated TPA-treatment (Figure 1d ). BMP-6 speci®c reactivity was mainly seen in the stratum granulosum and stratum corneum. This expression pattern persisted for at least 96 h after cessation of treatment (data not shown). In conclusion, BMP-6 is readily induced at the protein level after a single TPA-treatment. Repeated administration of this tumor promoter does not result in an adaptation process.
We quanti®ed BMP-6 RNA concentration in newborn wild-type mice, untreated and TPA-treated wildtype mice by real-time RT-PCR ( Figure 1e ). In accordance with immunohistochemical data, the mRNA level was very high in newborn mice and low in untreated adult mice. Despite increased protein levels, however, BMP-6 RNA levels in skin of TPAtreated mice at 24 h post treatment were as low as in adult control mice (Figure 1e ). Also, BMP-6 is not induced by TPA in the cultured keratinocyte cell line HaCaT at 6 h post treatment as demonstrated by competitive RT ± PCR analysis (Figure 1f) . Thus, induction of BMP-6 during tumor promotion is due to a post-transcriptional control mechanism.
Increased mitotic indices in the epidermis of BMP-6 transgenic mice S phase nuclei in wild-type and BMP-6 transgenic mice were depicted by BrdUrd labeling experiments, as exempli®ed in Figure 2a ,b. Untreated wild-type mice showed a frequency of 2.2 proliferating cells per 100 total basal keratinocytes, whereas BMP-6 transgenics show a frequency of 4.3 proliferating cells per 100 total basal keratinocytes (Figure 2c ). TPA is a potent tumor Figure 1 Expression of BMP-6 in the epidermis of wild-type mice. Immunostaining of skin sections with a monoclonal antibody directed against the pro-region of BMP-6, from (a) perinatal skin, (b) adult skin, (c) adult skin 24 h after TPA application, and (d) adult skin after 8 weeks of repeated TPA administration, 24 h post last application. Long-time promotion by TPA results in strong induction of BMP-6 expression in highly dierentiated keratinocytes. Bars: 100 mm. (e) Quantitative analysis of BMP-6 mRNA levels by real time RT ± PCR (TaqMan). RNA was prepared from wild-type skin tissue of untreated wild-type newborn and adult mice, as well as from TPA-treated adult mice. Skin was taken at the indicated timepoints after TPA-treatment. Note the unchanged BMP-6 RNA levels in treated and untreated skin. (f) Competitive RT ± PCR analysis of BMP-6 RNA levels in HaCaT cells without (lane 1) and 6 h post TPA treatment (lane 2). Note the largely unchanged ratio of speci®c product to competitor in both lanes promoter, known to stimulate mitotic activity and to induce hyperplasia of the skin after a single topical application. Twenty-four hours after a single dose of TPA, the number of S phase nuclei in the basal layer of both non-transgenic and transgenic mice increased approximately 10-fold, and subsequently decreased to basal levels within 96 h post application (Figure 2c ). At nearly every timepoint, mitotic indices in transgenics surpassed the respective controls by a factor of approximately 1.5.
Repeated TPA administration for 8 weeks, resulted in epidermal hyperproliferation in both experimental groups. When measured 24 h after the last treatment, the proliferation rate was lower compared to the acute response following a single dose TPA-administration ( Figure 2c ). However, epidermal mitotic indices in transgenic mice surpassed their respective controls by a factor of three which was twice as much compared to the acute response ( Figure 2c ). Thus, the pro-mitogenic activity of transgene derived BMP-6, as seen in untreated transgenic mice, is even enhanced during tumor promotion.
BMP-6 suppresses benign tumor and carcinoma growth in vivo
Wild-type and BMP-6 transgenic mice were initiated by DMBA treatment followed by tumor promotion with TPA twice weekly. The percentage of animals stricken with benign and malignant tumors is shown in progress curves ( Figure 3a ). BMP-6 transgenic mice showed a delayed formation of both papillomas and carcinomas in comparison to the control mice. At week 35 post initiation, in both groups, 95% of animals had papillomas. Carcinomas were present in 70% of the control mice, but only 38% of the transgenic mice ( Figure 3a) . After 55 weeks, over 90% of the animals in both groups carried carcinomas (data not shown).
The tumor load per animal, however, was signi®-cantly higher in non-transgenic controls versus BMP-6 transgenic mice, at all times. At 35 weeks post initiation, the number of papillomas per mouse was fourfold higher in the control group as compared to transgenics (Figure 3b) . Similarly, an approximately threefold higher carcinoma frequency was observed in wild-type mice at 35 weeks post initiation (Figure 3c ). These data strongly suggest that, at early stages of chemical skin carcinogenesis, keratinocytes derived To examine the eciency of tumor initiation by DMBA, we carried out a mutation analysis of the Hras gene, especially the A?T-transversion in codon 61 of exon 2, a known DMBA-induced mutational hotspot. Analyses of tumor-derived DNAs from both groups showed no signi®cant dierences in the percentage of tumors carrying this particular H-ras mutation. Mutation were detectable in 79.5% of all examined tumors in wild-type mice and in 78.6% of all transgenic mouse tumors (Table 1) .
BMP-6 induces apoptosis
Apoptosis in the epidermis was analysed by triplelabeling, using the TUNEL-assay for detection of apoptotic cells, the anti-keratin 14 staining for identi®cation of the epidermal layers ( Figure 4a ) and counterstaining with DAPI ( Figure 4b ) for the quantitative analysis of cellular nuclei. Only TUNELpositive nuclei in the basal layer of interfollicular epidermis were counted and related to the number of total basal nuclei. A 4.5-fold higher number of TUNEL-positive apoptotic keratinocytes was detected in the basal layer of untreated BMP-6 transgenic mice in comparison to the untreated non-transgenic controls. In non-transgenic mice the rate of apoptosis was 0.28 per 100 DAPI-labeled basal nuclei and in transgenic mice 1.25 apoptotic cells per 100 DAPIlabeled basal nuclei (Figure 4c) .
To test the in¯uence of TPA on apoptosis, mice were treated once with TPA and skin samples were taken 72 h later. There was a noticeable induction of apoptosis by TPA (Figure 4c ). In non-transgenic controls, the rate of apoptosis rose to 0.91, a threefold induction, but the TPA-induced increase of apoptotic cells in BMP-6 transgenic mice only rose from 1.25 to 1.57 (Figure 4c ). In summary, TPA induced apoptosis 72 h after treatment in both groups, but the rate of apoptosis was higher in transgenics versus non-transgenics in both normal and TPA-treated epidermis (Figure 4c ).
To examine whether the pro-apoptotic eect of BMP-6 was a result of a dierential expression of genes relevant to apoptosis, we analysed the mRNAs, extracted from control skin and transgenic skin, by RNase protection assays. In regard to transcript concentrations, no obvious changes were observed for the genes bcl-W, b¯l, bcl-X, bak, bcl-2 and bad. A marginal induction of bax could be observed (data not shown).
AP-1 family members are downregulated on the RNAlevel after TPA-treatment in BMP-6 transgenic mice
We determined the steady-state levels of mRNAs encoding the jun and fos family members in nontransgenic and transgenic animals before and after a single dose of TPA treatment. For each parameter setting, three animals were examined. In skin of untreated transgenic mice, the c-fos mRNA concentrations were nearly twice as high in comparison to wildtype mice (Figure 5a ). However, 24 h after TPA treatment, there was a signi®cant decrease in c-fos mRNA in the skin of transgenic mice, which was even more pronounced after 48 h. A similar downregulation of fra-1, fra-2 and fos-B in transgenic skin could be observed after TPA-treatment (Figure 5a ). In parallel, the mRNA concentrations of the jun family members c- 
Discussion
Factors modulating cell proliferation, apoptosis and in¯ammation are crucial to tumor promotion. In the present study, we show that administration of the tumor promoter TPA to dorsal skin of mice induces high levels of BMP-6 in the suprabasal, dierentiated epidermal keratinocytes. However, BMP-6 mRNA levels remain unchanged, suggesting post-transcriptional control mechanisms regulating expression of BMP-6. Similar observations had been described in human and murine skin wounds (Kaiser et al., 1998) as well as in hypertrophic cartilage and primary oocytes (Wall et al., 1993) .
The in¯uence of BMP-6 on keratinocyte growth was initially shown to be strongly inhibitory in cultured cells transfected with a retroviral BMP-6 expression vector (Drozdo et al., 1994) . However, in vivo experiments with BMP-6 transgenic mice, demonstrated that BMP-6 may also evoke epidermal hyperproliferation and in¯ammation (Blessing et al., 1996) . Similar ®ndings of a growth factor evoking either repression or stimulation of keratinocyte proliferation had been reported for TGF-b1 (Cui et al., 1996; Sellheyer et al., 1993) . To elucidate the role of BMP-6 induction during skin tumor promotion, we analysed transgenic mice of line VI-6-32 which overexpress BMP-6 epidermally (Blessing et al., 1996) .
In a two-step skin carcinogenesis protocol, BMP-6 transgenic mice showed a delayed formation of benign and malignant skin tumors as well as an overall reduction of tumor frequencies. These ®ndings are in good agreement with previously published data on other TGF-û family members, TGF-û1 and BMP-4 (Amendt et al., 1998; Blessing et al., 1995 , Cui et al., 1996 . However, this resistance to tumor development in BMP-6 transgenics sharply contrasts with its stimulation of epidermal hyperproliferation and inammation, hallmarks of ongoing tumor promotion (Blessing et al., 1996; DiGiovanni, 1991 DiGiovanni, , 1992 . In addition, there was no obvious dierence between transgenic and control mice in regard to tumor initiation, as re¯ected by comparable frequencies of activating H-ras gene mutations (Bailleul et al., 1990; Brown et al., 1986) . Thus, the anti-tumorigenic eect of BMP-6 is likely to act on the level of tumor promotion.
Apoptosis is a process which might counteract the clonal expansion of initiated cells during tumor promotion. TGF-b1 is known to induce apoptosis in various cell-types (Guo and Kyprianou, 1999; Motyl et al., 1998; Teramoto et al., 1998) and a requirement of BMP-2, -4 and -7 to initiate cell death in limb interdigital tissue is well established (Merino et al., 1998; Tang et al., 2000; Yokouchi et al., 1996) . Our ®ndings show that epidermal apoptotic frequencies in BMP-6 transgenic mice are elevated both in unchallenged skin and during tumor promotion suggesting that BMP-6 can induce apoptosis in keratinocytes. Since the increase in apoptotic frequencies surpasses the increase of mitotic indices, the observed epidermal thickening in transgenics is most likely due to an altered pathway of keratinocyte dierentiation and altered transit times (Blessing et al., 1996; Potten, 1975; Potten et al., 1984) . This pro-apoptotic activity of BMP-6 is associated with a reduced susceptibility towards skin carcinogenesis in the BMP-6 transgenic mice.
Furthermore, BMP-6 may contribute to tumor resistance through its eect on the expression of AP-1 components. AP-1 regulates a number of genes, some of which may mediate neoplastic transformation (Angel et al., 1987; Matrisian, 1994) . In vivo experiments have been performed for c-fos and c-jun to examine the function of AP-1 family members in multistage mouse skin carcinogenesis. Knock-out mice Figure 5 RPA-analysis of expression levels of mRNAs for the members of the jun and fos families in wild-type and BMP-6 transgenic mice, before and after TPA-treatment. (a) Relative levels of expression of the fos family members c-fos, fos-B, fra-1 and fra-2. No changes were detectable in wild-type mice after TPA-application, but transgenic mice show a downregulation of all fos mRNAs 24 h after TPA-treatment and even stronger after 48 h. In untreated transgenic mice, a twofold higher steady-state transcript concentration of c-fos is detectable. (b) Relative levels of expression of the jun family members c-jun, jun-B and jun-D. No changes were seen in wild-type mice after TPA-treatment, whereas in transgenic mice a reduction of all mRNAs of the jun family was observed 24 h and 48 h after TPA-application. (a, b) P-values were calculated by two-factorial ANOVA for the dierential reaction of the two genotypes to treatment. Values for P50.05 are considered signi®cant for c-fos show phorbol ester-induced papillomas, which do not convert to carcinomas, suggesting that c-fos is required for tumor conversion, but is not necessary for the formation of papillomas (Greenhalgh et al., 1995; Saez et al., 1995) . The role of c-jun in skin carcinogenesis was examined in transgenic mice, expressing a dominant negative derivative of c-jun (Young et al., 1999) . In the skin carcinogenesis model, these mice are protected against skin tumor formation by DMBA/TPA despite the fact that TPA-induced hyperproliferation is not inhibited. Thus, hyperproliferation per se, even in combination with in¯ammation, is not sucient for tumor promotion. In addition, AP-1 activity is essential.
TGF-b family members can regulate the expression of jun and fos family members on the transcriptional level. The c-fos gene can be activated by TGF-b1 (Choi et al., 1999; Ueyama et al., 1998) and the transcription of junB can be induced by BMP-2 and BMP-4 (Hollnagel et al., 1999) . In the junB promoter, a Smad-binding site was identi®ed, which seems to be a TGF-b, activin and BMP inducible enhancer (Jonk et al., 1998) . The eect of BMP-6 on AP-1 component expression in vivo is biphasic. On the one hand, simple overexpression of BMP-6 in interfollicular epidermis increased the RNA levels for c-fos, implying that BMP-6 can induce expression of AP-1 components like its relatives BMP-2 and -4 (Hollnagel et al., 1999) . Induction of c-fos by BMP-6 also explains the observed hyperproliferation in BMP-6 transgenics, since overexpression of active derivatives of this AP-1 constituent (v-fos) induce epidermal hyperplasia and hyperkeratosis . On the other hand, a dramatic reduction of RNA levels for fos/jun family members was observed in BMP-6 transgenics at 24 h and 48 h post TPA treatment. In wild-type mice, no changes in jun or fos expression were observed at these timepoints because jun and fos are immediate early genes and their maximal activation in skin by TPA occurs already 3 h post application (Kennard et al., 1995) . It is well known that AP-1 activity is modulated by post-transcriptional mechanisms, however, in TPAtreated keratinocytes changes in AP-1 activity correlate well with changes in RNA-levels for individual components (Dotto et al., 1986; Rutberg et al., 1997; Younus and Gilchrest, 1992) . In view of the fact that both c-jun and c-fos are required for skin carcinogenesis (Saez et al., 1995; Young et al., 1999) , the repression of expression of these factors by BMP-6 during tumor promotion probably is the second mechanism besides increased apoptotic frequencies establishing resistance to skin tumor induction.
Material and methods

Animals
BMP-6 transgenic mice of line VI-6-32 (Blessing et al., 1996; Kaiser et al., 1998) and non-transgenic controls were maintained on an inbred FVB/N background.
Immunohistochemistry and in situ hybridization experiments
Shaved dorsal skin of 8-week-old, age and sex matched mice were treated with a single dose of TPA (2.5 mg resolved in 200 ml ice-cold acetone) or treated twice weekly with TPA for 8 weeks. The animals were sacri®ced 24, 48, 72 and 96 h after the last treatment and skin samples were frozen. For BMP-6 immunohistochemistry we used a biotin-conjugated monoclonal antibody, directed against the proregion of rat BMP-6, which also recognizes murine and human BMP-6 (morph-6.1, Biotin, mouse IgG1 anti-rat, T-3207, BMA Biochemicals AG, Augst, Switzerland). In addition, a polyclonal antibody which recognizes the proregion of human and mouse BMP-6 was used (Wall et al., 1993) . Cryosections of skin-tissue (4 mm) were ®xed in 4% paraformaldehyde for 20 min at room temperature. To quench endogeneous peroxidase activity, sections were incubated with DAKO 1 Biotin Blocking System (DAKO Corporation, Carpinteria, USA). The sections were blocked with 4% drymilk-powder in PBS, before incubation with the monoclonal anti-BMP-6 antibody (1 : 50 in 4% dry milk-powder) at 48C overnight. HRPconjugated streptavidin anti-biotin was diluted 1 : 500 in 4% dry milk-powder (SA 108, Chemicon, Hofheim, Germany). Substrate solution consisted of diaminobenzidine (DAB) and 0.02% hydrogen peroxide. In situ hybridization experiments were carried out as described previously (Kaiser et al., 1998) .
Real-time quantitative RT ± PCR analysis
The cDNA was generated from RNA from total mouse skin using a RT ± PCR kit according to the manufacturer's instructions (Stratagene, La Jolla, CA, USA). Quantitative real-time PCR reactions were carried out in the ABI PRISM 7700 Sequence Detector System (PE Applied Biosystems, Foster City, CA, USA) using reagents and conditions as suggested by the manufacturer. BMP-6 mRNA levels were analysed using the following primer pairs and the¯uorescent dye FAM labeled hybridization probe: forward primer 5'-CAC AGT CCT CTT CTT CGG GC-3' (position 1896 ± 1915; GenBank accession no. AH003686), reverse primer 5'-CTT TTG CAT CTC CCG CTT CT-3' (position 1962 CT-3' (position ± 1943 ; GenBank accession no. AH003686) and hybridization probe 5'-6FAM-CCT CTA TCG GCG GCT CAA GAC CCA- TAMRA-3' (position 1918 TAMRA-3' (position ± 1941 ; GenBank accession no. AH003686). As endogenous control, primer and hybridization probe for GAPDH were used with the following sequences: forward primer 5'-TCA CTG GCA TGG CCT TCC-3' (position 723 ± 740; GenBank accession no. M32599), reverse primer 5'-CAG GCG GCA CGT CAG AT-3' (position 787-771; GenBank accession no. M32599) and hybridization probe 5'-6FAM-TCC TAC CCC CAA TGT GTC CGT CGT-TAMRA-3' (position 745 ± 768; GenBank accession no. M32599). Quantitative analysis were performed as described in`Applied Biosystems ABI PRISM 7700. Sequence Detection System User Bulletin #2, Dec 11, 1997'.
Cell culture and competitive RT ± PCR
HaCaT cells were cultured in CG-Medium (Vitromex, Selters, Germany) with 0.5% FCS and penicillin ± streptomycin (Boukamp et al., 1988) . Cells were stimulated with 100 nM TPA (12-O-tetradecanoylphorbol-13-acetate; Sigma Chemical, St. Louis, MO, USA) as described previously (Denning et al., 1998) for 4, 6 and 24 h.
Total RNA was prepared with TRI REAGENT (Sigma Chemical, St. Louis, MO, USA) according to the manufacturer's instructions. Reverse Transcription was performed BMP-6 and skin carcinogenesis S Wach et al with the RNA PCR Kit Ver. 2.1 (Takara Shuzo Co., Otsa, Japan) according to the manufacturer's instructions. The amount of û-actin c-DNA in the probes was quanti®ed using the û-actin Competitive PCR Set (Takara Shuzo Co., Otsa, Japan) according to the manufacturer's instructions. In brief, using oligonucleotides û-actin S primer (5'-CAA GAG ATG GCC ACG GCT GCT-3'; position 2338 ± 2358; GenBank accession no. M10277) and û-actin A primer (5'-TCC TTC TGC ATC CTG TCG GCA-3'; position 2707 ± 2687; GenBank accession no. M10277) a fragment of 275 bp with human û-actin c-DNA as template and a fragment of 340 bp with human û-actin DNA competitor as template were generated. Using this system cDNA concentrations were normalized in relation to û-actin RNA content. BMP-6 speci®c transcripts were detected using oligonucleotides hBMP-6-3 (5'-caa cag agt cgt aat cgc tc; position 1323 ± 1342; GenBank accession no. XM_004464) and hBMP-6-4 (5'-gtt gca ttc atg tgt gcg-3'; position 1546 ± 1529; GenBank accession no XM_004464). The length of the diagnostic fragment was 224 bp.
We generated a competitive DNA as described (Ross et al., 1995) using the hybrid primers Hyb S (5'-cag agt cgt aat cgc GGT CAG AAG GAT TCC-3') and Hyb AS (5'-gca ttc atg tgt gcg GTC ACC GGA GTC CAT-3'). BMP-6 speci®c sequences (lower case) are described above. The û-actin part (upper case) of Hyb S corresponds to position 1366 ± 1380; GenBank accession no. M10277), the û-actin part (upper case) of Hyb AS corresponds to position 2137 ± 2122; GenBank accession no. M10277). The resulting competitive DNA was a û-actin c-DNA with BMP-6 speci®c primer binding sites. The ampli®cation product had a length of 359 bp. BMP-6 RNA levels were assessed by comparing the band intensities of the speci®c product (224 bp) to the competitor (359 bp) using cDNA samples normalized to û-actin content as templates.
BrdUrd-labeling experiments
BrdUrd-labeling experiments were performed to identify nuclei in S phase of the cell cycle (`In Situ Cell Proliferation Kit, AP'; Boehringer Mannheim, Mannheim, Germany). Age and sex matched transgenic animals and normal controls received a single injection of BrdUrd (30 mg per gram body weight) and were sacri®ced 1 h after the injection. Tissue samples were embedded in freeze-medium and frozen in liquid nitrogen. Fixation and processing of the samples were performed according to the instructions of Boehringer Mannheim. Tissue samples were counterstained with hematoxylin. The number of labeled S phase nuclei in the basal layer of interfollicular epidermis was determined and related to 100 total basal cells. For each experiment, values were obtained from at least three animals per group.
Chemical carcinogenesis
Each experimental group consisted of 22 mice. Initiation and promotion were performed essentially as described previously (DiGiovanni, 1991; Hennings et al., 1993) . At the age of 8 weeks, animals were shaved prior to topical applications of two doses of 100 mg of the tumor initiator 7,12-dimethylbenz(a)anthracene (DMBA), dissolved in 200 ml of ice-cold acetone. For tumor promotion, animals were treated twice weekly with TPA (2.5 mg dissolved in 200 ml of ice-cold acetone). Development of lesions was monitored once weekly. Carcinomas were veri®ed and graded histologically after hematoxylin and eosin-staining of sections.
Detection of H-ras mutation
DNA samples from skin tumors of both transgenic and nontransgenic mice were ampli®ed by hot start PCR with primers speci®c for H-ras, exon 2. Primer sequences: H-ras southern I 5'-GCT GTG GCA GTG GTC ATG G-3' (position 140 ± 158; GenBank accession no. Z50013) and H-ras southern II 5'-GGG GTG GAT ATG AGC CAG C-3' (position 638 ± 620; GenBank accession no. Z50013). Each PCR reaction comprised 35 cycles with an annealing temperature of 618C. PCR-products were puri®ed and cut with the restriction enzyme XbaI (cuts selectively the sequence with an A-Ttransversion). Samples were separated on 1.5% agarose-gels, prior to southern blotting. Hybridization probes were generated by PCR as described above, and labeled with 32 P. Intensity of bands was analysed by autoradiography and the Image-Quant System (Molecular Dynamics, Sunnyvale, USA). Wild-type alleles yielded a 500 bp fragment, whereas mutated alleles yielded fragments of 250 bp.
Fluorescent TUNEL-labeling/K14-Immunohistochemistry/ DAPI
Detection and quanti®cation of apoptosis in the epidermis were performed using the`In Situ Cell Death Detection Kit, FLUOS' (Boehringer Mannheim). Fresh 4 mm cryosections from skin-tissue were ®xed and processed according to the manufacturer's instructions. Sections were also incubated with an anti-cytokeratin 14 antibody (dilution 1 : 1000) (Amendt et al., 1998) as a marker for the epidermal basal layer. Goat-anti-rabbit IgG, conjugated with Cy TM 3 (1 : 800; Dianova, Hamburg, Germany) was used as secondary antibody. For counterstaining, the nuclei were labeled with DAPI (4',6-Diamin-2'-phenylindol-dihydrochloride; Boehringer Mannheim). The number of apoptotic cells in the basal layer of the epidermis was determined and related to 100 total basal cell nuclei. Nuclei were counted from sections of at least three age-and sex-matched animals per group.
RNase protection assay (RPA)
RPAs were performed using the RiboQuant Multi-Probe RNase Protection Assay System, which includes thè RiboQuant TM In Vitro Transcription Kit' (45005K; Pharmingen, San Diego, USA), the`RPA Kit' (45014K; Pharmingen) and the Multi-Probe Template Sets mAPO2 (45354P; Pharmingen) and mFos/Jun (45357P; Pharmingen) according to the manufacturer's instructions. Total RNA was isolated from skin samples using peqGOLD RNA Pure (Peqlab Biotechnologie, Erlangen, Germany). Reaction mixtures were separated by 6% Urea/PAGE and band intensity was quanti®ed using the Image-Quant System (Molecular Dynamics). Band intensities from the apoptosisrelevant mRNAs and the fos/jun family members were related to band intensities from the housekeeping gene L32. Statistical analysis was performed by two-factorial ANOVA with genotype and treatment as variables. P-values were calculated for the dierential reactions of the two genotypes to treatment. gemeinschaft in program`Graduiertenkolleg Molekulare und zellulaÈ re Mechanismen der Pathogenese' to S Wach and a grant from the Boehringer Ingelheim Foundation to M Blessing. We thank K Petmecky for technical assistance, T Schild for technical support in TaqMan-analysis and K-J Kallen for reading the manuscript.
